These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 33628239)

  • 21. Dynamic susceptibility contrast (DSC) perfusion MRI in differential diagnosis between radionecrosis and neoangiogenesis in cerebral metastases using rCBV, rCBF and K2.
    Muto M; Frauenfelder G; Senese R; Zeccolini F; Schena E; Giurazza F; Jäger HR
    Radiol Med; 2018 Jul; 123(7):545-552. PubMed ID: 29508242
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Perfusion magnetic resonance imaging for high grade astrocytomas: Can cerebral blood volume, peak height, and percentage of signal intensity recovery distinguish between progression and pseudoprogression?].
    Martínez-Martínez A; Martínez-Bosch J
    Radiologia; 2014; 56(1):35-43. PubMed ID: 23790618
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Perfusion magnetic resonance imaging in the differentiation between glioma recurrence and pseudoprogression: a systematic review, meta-analysis and meta-regression.
    Zhang J; Wang Y; Wang Y; Xiao H; Chen X; Lei Y; Feng Z; Ma X; Ma L
    Quant Imaging Med Surg; 2022 Oct; 12(10):4805-4822. PubMed ID: 36185045
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modification of MRI pattern of high-grade glioma pseudoprogression in regorafenib therapy.
    Mansour M; Vitale V; Lombardi G; Riva G; Pancheri F; Zanusso M
    J Med Imaging Radiat Oncol; 2022 Apr; 66(3):414-418. PubMed ID: 34169667
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Magnetic resonance spectroscopy outperforms perfusion in distinguishing between pseudoprogression and disease progression in patients with glioblastoma.
    El-Abtah ME; Talati P; Fu M; Chun B; Clark P; Peters A; Ranasinghe A; He J; Rapalino O; Batchelor TT; Gilberto Gonzalez R; Curry WT; Dietrich J; Gerstner ER; Ratai EM
    Neurooncol Adv; 2022; 4(1):vdac128. PubMed ID: 36071927
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial.
    Liu ZC; Yan LF; Hu YC; Sun YZ; Tian Q; Nan HY; Yu Y; Sun Q; Wang W; Cui GB
    BMC Med Imaging; 2017 Feb; 17(1):10. PubMed ID: 28143434
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interval Change in Diffusion and Perfusion MRI Parameters for the Assessment of Pseudoprogression in Cerebral Metastases Treated With Stereotactic Radiation.
    Knitter JR; Erly WK; Stea BD; Lemole GM; Germano IM; Doshi AH; Nael K
    AJR Am J Roentgenol; 2018 Jul; 211(1):168-175. PubMed ID: 29708785
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DCE and DSC MR perfusion imaging in the differentiation of recurrent tumour from treatment-related changes in patients with glioma.
    Shin KE; Ahn KJ; Choi HS; Jung SL; Kim BS; Jeon SS; Hong YG
    Clin Radiol; 2014 Jun; 69(6):e264-72. PubMed ID: 24594379
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessing the diagnostic accuracy and interobserver agreement of MRI perfusion in differentiating disease progression and pseudoprogression following treatment for glioblastoma in a tertiary UK centre.
    Maiter A; Butteriss D; English P; Lewis J; Hassani A; Bhatnagar P
    Clin Radiol; 2022 Aug; 77(8):e568-e575. PubMed ID: 35636976
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glioblastoma treated with concurrent radiation therapy and temozolomide chemotherapy: differentiation of true progression from pseudoprogression with quantitative dynamic contrast-enhanced MR imaging.
    Yun TJ; Park CK; Kim TM; Lee SH; Kim JH; Sohn CH; Park SH; Kim IH; Choi SH
    Radiology; 2015 Mar; 274(3):830-40. PubMed ID: 25333475
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma recurrence from posttreatment effects.
    Fink JR; Carr RB; Matsusue E; Iyer RS; Rockhill JK; Haynor DR; Maravilla KR
    J Magn Reson Imaging; 2012 Jan; 35(1):56-63. PubMed ID: 22002882
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New Subependymal Enhancement After Radiation Therapy in High-Grade Glioma: Utilizing Morphological Features and DSC Perfusion MRI in Differentiate Progression and Post-Radiation Changes.
    Choi KS; Hwang I; Park CK; Park SH; Choi SH
    J Magn Reson Imaging; 2024 Sep; ():. PubMed ID: 39238277
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The diagnostic performance of magnetic resonance spectroscopy in differentiating high-from low-grade gliomas: A systematic review and meta-analysis.
    Wang Q; Zhang H; Zhang J; Wu C; Zhu W; Li F; Chen X; Xu B
    Eur Radiol; 2016 Aug; 26(8):2670-84. PubMed ID: 26471274
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differentiation of Glioblastoma and Solitary Brain Metastasis by Gradient of Relative Cerebral Blood Volume in the Peritumoral Brain Zone Derived from Dynamic Susceptibility Contrast Perfusion Magnetic Resonance Imaging.
    She D; Xing Z; Cao D
    J Comput Assist Tomogr; 2019; 43(1):13-17. PubMed ID: 30015801
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diffusion and perfusion MRI to differentiate treatment-related changes including pseudoprogression from recurrent tumors in high-grade gliomas with histopathologic evidence.
    Prager AJ; Martinez N; Beal K; Omuro A; Zhang Z; Young RJ
    AJNR Am J Neuroradiol; 2015 May; 36(5):877-85. PubMed ID: 25593202
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DSC and DCE Histogram Analyses of Glioma Biomarkers, Including IDH, MGMT, and TERT, on Differentiation and Survival.
    Zhang HW; Lyu GW; He WJ; Lei Y; Lin F; Wang MZ; Zhang H; Liang LH; Feng YN; Yang JH
    Acad Radiol; 2020 Dec; 27(12):e263-e271. PubMed ID: 31983532
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Visual inspection of MR relative cerebral blood volume maps has limited value for distinguishing progression from pseudoprogression in glioblastoma multiforme patients.
    Kerkhof M; Tans PL; Hagenbeek RE; Lycklama À Nijeholt GJ; Holla FK; Postma TJ; Straathof CS; Dirven L; Taphoorn MJ; Vos MJ
    CNS Oncol; 2017 Oct; 6(4):297-306. PubMed ID: 28984142
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differentiating surgical from non-surgical lesions using perfusion MR imaging and proton MR spectroscopic imaging.
    Law M; Hamburger M; Johnson G; Inglese M; Londono A; Golfinos J; Zagzag D; Knopp EA
    Technol Cancer Res Treat; 2004 Dec; 3(6):557-65. PubMed ID: 15560713
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic performance of perfusion MRI in differentiating low-grade and high-grade gliomas: advanced MRI in glioma, A Siriraj project.
    Direksunthorn T; Chawalparit O; Sangruchi T; Witthiwej T; Tritrakarn SO; Piyapittayanan S; Charnchaowanish P; Pornpunyawut P; Sathornsumetee S
    J Med Assoc Thai; 2013 Sep; 96(9):1183-90. PubMed ID: 24163995
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Perfusion MRI (dynamic susceptibility contrast imaging) with different measurement approaches for the evaluation of blood flow and blood volume in human gliomas.
    Thomsen H; Steffensen E; Larsson EM
    Acta Radiol; 2012 Feb; 53(1):95-101. PubMed ID: 22114021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.